×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NYSE:MRK

Merck & Co., Inc. Stock Forecast, Price & News

$92.42
+1.25 (+1.37%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$90.39
$92.49
50-Day Range
$84.41
$94.64
52-Week Range
$70.89
$95.72
Volume
11.41 million shs
Average Volume
12.45 million shs
Market Capitalization
$233.71 billion
P/E Ratio
16.53
Dividend Yield
2.99%
Price Target
$92.82

Merck & Co., Inc. Stock Forecast (MarketRank)

Analyst Rating
Moderate Buy
2.53 Rating Score
Upside/​Downside
0.4% Upside
$92.82 Price Target
Short Interest
Healthy
0.79% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.29
Upright™ Environmental Score
News Sentiment
0.43mentions of Merck & Co., Inc. in the last 14 days
Based on 19 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-1.78%
From $7.32 to $7.19 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.24 out of 5 stars

Medical Sector

222nd out of 1,428 stocks

Pharmaceutical Preparations Industry

105th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive MRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter.

Merck & Co., Inc. logo

About Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

MRK Stock News Headlines

3 Reasons Why Merck (MRK) Is a Great Growth Stock
Merck & Co., Inc. (NYSE:MRK) PT Raised to $102.00
8 Analysts Have This to Say About Merck & Co
Seagen Would Be A Great Fit For Merck
Mizuho Initiates Coverage on Merck & Co., Inc. (NYSE:MRK)
Merck/Seagen Potential Deal Talks Pick Up Speed: WSJ
Merck Pushes Forward With Potential Deal for Seagen
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
58933Y10
Employees
68,000
Year Founded
1891

Company Calendar

Ex-Dividend for 4/7 Dividend
3/14/2022
Dividend Payable
4/07/2022
Last Earnings
4/28/2022
Ex-Dividend for 7/8 Dividend
6/14/2022
Today
7/03/2022
Dividend Payable
7/08/2022
Next Earnings (Confirmed)
7/28/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$92.82
High Stock Price Forecast
$110.00
Low Stock Price Forecast
$70.00
Forecasted Upside/Downside
+0.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.52941176470588
Research Coverage
17 Analysts

Profitability

Net Income
$13.05 billion
Pretax Margin
29.18%

Debt

Sales & Book Value

Annual Sales
$48.70 billion
Cash Flow
$7.32 per share
Book Value
$15.14 per share

Miscellaneous

Outstanding Shares
2,528,800,000
Free Float
2,521,471,000
Market Cap
$233.71 billion
Optionable
Optionable
Beta
0.35

Social Links















Merck & Co., Inc. Frequently Asked Questions

Should I buy or sell Merck & Co., Inc. stock right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last twelve months. There are currently 9 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Merck & Co., Inc. stock.
View analyst ratings for Merck & Co., Inc.
or view top-rated stocks.

What is Merck & Co., Inc.'s stock price forecast for 2022?

17 analysts have issued 1-year target prices for Merck & Co., Inc.'s stock. Their MRK stock forecasts range from $70.00 to $110.00. On average, they predict Merck & Co., Inc.'s share price to reach $92.82 in the next year. This suggests a possible upside of 0.4% from the stock's current price.
View analysts' price targets for Merck & Co., Inc.
or view top-rated stocks among Wall Street analysts.

How has Merck & Co., Inc.'s stock performed in 2022?

Merck & Co., Inc.'s stock was trading at $76.64 at the start of the year. Since then, MRK stock has increased by 20.6% and is now trading at $92.42.
View the best growth stocks for 2022 here
.

When is Merck & Co., Inc.'s next earnings date?

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Thursday, July 28th 2022.
View our earnings forecast for Merck & Co., Inc.
.

How can I listen to Merck & Co., Inc.'s earnings call?

Merck & Co., Inc. will be holding an earnings conference call on Thursday, July 28th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) announced its earnings results on Thursday, April, 28th. The company reported $2.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.81 by $0.33. The business had revenue of $15.90 billion for the quarter, compared to analysts' expectations of $14.64 billion. Merck & Co., Inc. had a net margin of 26.27% and a trailing twelve-month return on equity of 47.86%. The business's quarterly revenue was up 31.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.40 EPS.
View Merck & Co., Inc.'s earnings history
.

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. declared a quarterly dividend on Tuesday, May 24th. Stockholders of record on Wednesday, June 15th will be given a dividend of $0.69 per share on Friday, July 8th. This represents a $2.76 dividend on an annualized basis and a yield of 2.99%. The ex-dividend date is Tuesday, June 14th.
View Merck & Co., Inc.'s dividend history
.

Is Merck & Co., Inc. a good dividend stock?

Merck & Co., Inc.(NYSE:MRK) pays an annual dividend of $2.76 per share and currently has a dividend yield of 2.99%. Merck & Co., Inc. has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Merck & Co., Inc. is 49.37%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 38.33% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.
View Merck & Co., Inc.'s dividend history.

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of $7.24-$7.36 for the period, compared to the consensus estimate of $7.24. The company issued revenue guidance of $56.90 billion-$58.10 billion, compared to the consensus revenue estimate of $57.35 billion.

Who are Merck & Co., Inc.'s key executives?

Merck & Co., Inc.'s management team includes the following people:

What is Kenneth C. Frazier's approval rating as Merck & Co., Inc.'s CEO?

1,343 employees have rated Merck & Co., Inc. CEO Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among Merck & Co., Inc.'s employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and Home Depot (HD).

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Cacti Asset Management LLC (0.03%), Park National Corp OH (0.00%), Chemung Canal Trust Co. (0.00%), First Financial Bank Trust Division (0.00%), Stonebridge Capital Management Inc. (0.00%) and Insight Wealth Strategies LLC (0.00%). Company insiders that own Merck & Co., Inc. stock include Caroline Litchfield, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Richard R Deluca, Rita A Karachun, Robert M Davis, Sanat Chattopadhyay and Wendell P Weeks.
View institutional ownership trends for Merck & Co., Inc.
.

Which major investors are selling Merck & Co., Inc. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including Park National Corp OH, Stonebridge Capital Management Inc., First Financial Bank Trust Division, and Chemung Canal Trust Co.. Company insiders that have sold Merck & Co., Inc. company stock in the last two years include Caroline Litchfield, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Richard R Deluca, Rita A Karachun, Robert M Davis, and Sanat Chattopadhyay.
View insider buying and selling activity for Merck & Co., Inc.
or view top insider-selling stocks.

Which major investors are buying Merck & Co., Inc. stock?

MRK stock was acquired by a variety of institutional investors in the last quarter, including Insight Wealth Strategies LLC, and Cacti Asset Management LLC.
View insider buying and selling activity for Merck & Co., Inc.
or or view top insider-buying stocks.

How do I buy shares of Merck & Co., Inc.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $92.42.

How much money does Merck & Co., Inc. make?

Merck & Co., Inc. (NYSE:MRK) has a market capitalization of $233.71 billion and generates $48.70 billion in revenue each year. The company earns $13.05 billion in net income (profit) each year or $5.59 on an earnings per share basis.

How many employees does Merck & Co., Inc. have?

Merck & Co., Inc. employs 68,000 workers across the globe.

When was Merck & Co., Inc. founded?

Merck & Co., Inc. was founded in 1891.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The official website for Merck & Co., Inc. is www.merck.com. The company can be reached via phone at (908) 740-4000, via email at investor_relations@merck.com, or via fax at 908-735-1253.

This page (NYSE:MRK) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.